Springer Protocols: Abstract: Target Validation Using RNA Interference in Solid Tumors

Target Validation Using RNA Interference in Solid Tumors

By: Seyedhossein Aharinejad², Mouldy Sioud³, Trevor Lucas², Dietmar Abraham²

Abstract

Full Text

Download PDF (542K)

Reverse genetics is one strategy that is currently used to establish a link between a target gene and a disease phenotype. In this process, the function of a gene is inhibited and the consequence of its loss on a desired biological function, such as tumor growth and metastasis, is monitored. RNA interference (RNAi) has been found to be the most effective method to specifically inhibit gene expression. Notably, interactions between cancer cells, stromal cells, and the extracellular matrix (ECM) are crucial to angiogenesis and tumorigenesis. Tumor cells and the surrounding stroma are the principle source of growth factors and cytokines, which induce remodeling of the ECM mediated by metalloproteases (MMPs) secreted by macrophages. The production of macrophages is regulated by colony-stimulating factor (CSF)-1, which is overexpressed in several tumors. When short-interfering RNAs (siRNAs) targeting either the CSF-1 or its receptors were delivered into colon and breast cancer xenografts in mice, tumor growth was inhibited. Associated with this suppression, we observed decreased tumor vascularity, reduced expression of angiogenic factors and MMPs, and decreased macrophage recruitment to the tumors. The suppression of CSF-1 by RNA interference is therefore a powerful tool to block gene function and influence tumor-stroma interactions in solid tumor development.

Affiliation(s): (2) Laboratory of Cardioascular Research, Center for Anatomy and Cell Biology, Vienna Medical University, Vienna, Austria
(3) Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

Book Title: Target Discovery and Validation Reviews and Protocols: Volume 2: Emerging Molecular Targets and Treatment Options

Series: Methods in Molecular Biology | Volume: 361 | Pub. Date: Feb-05-2007 | Page Range: 227-238 | DOI: 10.1385/1-59745-208-4:227

Subject: Pharmacology/Toxicology

Key Words: Reverse genetics - breast cancer - RNAi - siRNA - CSF-1

References

Download References

1.	Aharinejad, S., Marks, S. C., Jr., Bock, P., et al. (1995) CSF-1 treatment promotes angiogenesis in the metaphysis of osteopetrotic (toothless, tl) rats. Bone 16, 315–324. <Occurrence Type="DOI"><Handle>10.1016/8756-3282(94)00044-1</Handle></Occurrence>

2.	Aharinejad, S., Abraham, D., Paulus, P., et al. (2002) Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res. 62, 5317–5324.

3.	Aharinejad, S., Paulus, P., Sioud, M., et al. (2004) Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64, 5378–5384.

4.	Baiocchi, G., Kavanagh, J. J., Talpaz, M., Wharton, J. T., Gutterman, J. U., and Kurzrock, R. (1991) Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer 67, 990–996. <Occurrence Type="DOI"><Handle>10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8</Handle></Occurrence>

5.	Bast, R. C., Jr., Boyer, C. M., Jacobs, I., et al. (1993) Cell growth regulation in epithelial ovarian cancer. Cancer 71, 1597–1601.

6.	Caplen, N. J., Parrish, S., Imani, F., Fire, A., and Morgan, R. A. (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98, 9742–9747.

7.	Coussens, L. M. and Werb, Z. (1996) Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895–904. <Occurrence Type="DOI"><Handle>10.1016/S1074-5521(96)90178-7</Handle></Occurrence>

8.	Eubank, T. D., Galloway, M., Montague, C. M., Waldman, W. J., and Marsh, C. B. (2003) M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J. Immunol. 171, 2637–2643.

9.	Farber, E. (1984) The multistep nature of cancer development. Cancer Res. 44, 4217–4223.

10.	Fidler, I. J. and Ellis, L. M. (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185–188. <Occurrence Type="DOI"><Handle>10.1016/0092-8674(94)90187-2</Handle></Occurrence>

11.	Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58–61.

12.	Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27–31.

13.	Folkman, J. (1995) Angiogenesis inhibitors generated by tumors. Mol. Med. 1, 120–122.

14.	Goswami, S., Sahai, E., Wyckoff, J. B., et al. (2005) Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65, 5278–5283.

15.	Ingber, D. E. and Folkman, J. (1989) How does extracellular matrix control capillary morphogenesis? Cell 58, 803–805. <Occurrence Type="DOI"><Handle>10.1016/0092-8674(89)90928-8</Handle></Occurrence>

16.	James, S. L., Cook, K. W., and Lazdins, J. K. (1990) Activation of human monocyte-derived macrophages to kill schistosomula of Schistosoma mansoni in vitro. J. Immunol. 145, 2686–2690.

17.	Kacinski, B. M., Chambers, S. K., Stanley, E. R., et al. (1990) The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. Int. J. Radiat. Oncol. Biol. Phys. 19, 619–626.

18.	Kascinski, B. (2002) Expression of CSF-1 and its receptor CSF-1R in nonhematopoietic neoplasms. Cancer Treat. Res. 107, 285–292.

19.	Lidor, Y. J., Xu, F. J., Martinez-Maza, O., et al. (1993) Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp. Cell. Res. 207, 332–339.

20.	Lin, E. Y., Nguyen, A. V., Russell, R. G., and Pollard, J. W. (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740.

21.	Lin, E. Y., Gouon-Evans, V., Nguyen, A. V., and Pollard, J. W. (2002) The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland. Biol. Neoplasia. 7, 147–162.

22.	Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327–336. <Occurrence Type="DOI"><Handle>10.1016/0092-8674(91)90642-C</Handle></Occurrence>

23.	Liotta, L. A. and Kohn, E. C. (2001) The microenvironment of the tumour-host interface. Nature 411, 375–379.

24.	Lopez, M., Martinache, C., Canepa, S., Chokri, M., Scotto, F., and Bartholeyns, J. (1993) Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, IL-3 and M-CSF, their differentiation into macrophages. J. Immunol. Methods 159, 29–38. <Occurrence Type="DOI"><Handle>10.1016/0022-1759(93)90138-W</Handle></Occurrence>

25.	Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco, L. (1992) The origin and function of tumor-associated macrophages. Immunol. Today 13, 265–270. <Occurrence Type="DOI"><Handle>10.1016/0167-5699(92)90008-U</Handle></Occurrence>

26.	Nowicki, A., Szenajch, J., Ostrowska, G., et al. (1996) Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer 65, 112–119. <Occurrence Type="DOI"><Handle>10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.0.CO;2-I</Handle></Occurrence>

27.	Pei, X. H., Nakanishi, Y., Takayama, K., Bai, F., and Hara, N. (1999) Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br. J. Cancer 79, 40–46.

28.	Pixley, F. J. and Stanley, E. R. (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 14, 628–638.

29.	Pollard, J. W. (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78.

30.	Polverini, P. J., Cotran, P. S., Gimbrone, M. A., Jr., and Unanue, E. R. (1977) Activated macrophages induce vascular proliferation. Nature 269, 804–806.

31.	Roth, P. and Stanley, E. R. (1992) The biology of CSF-1 and its receptor. Curr. Top. Microbiol. Immunol. 181, 141–167.

32.	Russo, J. and Russo, I. H. (2001) The pathway of neoplastic transformation of human breast epithelial cells. Radiat. Res. 155, 151–154. <Occurrence Type="DOI"><Handle>10.1667/0033-7587(2001)155[0151:TPONTO]2.0.CO;2</Handle></Occurrence>

33.	Scholl, S. M., Pallud, C., Beuvon, F., et al. (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl. Cancer Inst. 86, 120–126.

34.	Sherr, C. J., Rettenmier, C. W., Sacca, R., Roussel, M. F., Look, A. T., and Stanley, E. R. (1985) The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41, 665–676. <Occurrence Type="DOI"><Handle>10.1016/S0092-8674(85)80047-7</Handle></Occurrence>

35.	Sioud, M. (2004) Therapeutic siRNAs. Trends Pharmacol. Sci. 25, 22–28.

36.	Stanley, E. (1992) Interleukins, in Human Cytokines, (Aggarwal, B. and Gutterman, J., eds.), Blackwell, Boston, MA, pp. 196–220.

37.	Nowicki A, Szenajch J, Ostrowska G, et al. (1996). Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J. Cancer. 65, 112–119. <Occurrence Type="DOI"><Handle>10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.0.CO;2-I</Handle></Occurrence>

38.	Stein, C. A. (2001) The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. 108, 641–644.

39.	Stetler-Stevenson, W. G. and Yu, A. E. (2001) Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11, 143–152.

40.	Sunderkotter, C., Goebeler, M., Schulze-Osthoff, K., Bhardwaj, R., and Sorg, C. (1991) Macrophage-derived angiogenesis factors. Pharmacol. Ther. 51, 195–216. <Occurrence Type="DOI"><Handle>10.1016/0163-7258(91)90077-Y</Handle></Occurrence>

41.	Sunderkotter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., and Sorg, C. (1994) Macrophages and angiogenesis. J. Leukoc. Biol. 55, 410–422.

42.	Suzuki, M., Ohwada, M., Aida, I., Tamada, T., Hanamura, T., and Nagatomo, M. (1993) Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet. Gynecol. 82, 946–950.

43.	Suzuki, M., Kobayashi, H., Ohwada, M., Terao, T., and Sato, I. (1998) Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary. Gynecol. Oncol. 68, 35–37.

44.	Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. (1991) Tumor angiogenesis and metastasis— correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8.

45.	Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J. (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401–409.

46.	Weinberg, R. A. (1989) Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49, 3713–3721.

47.	Werb, Z., Banda, M. J., and Jones, P. A. (1980) Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J. Exp. Med. 152, 1340–1357.

48.	Yeung, Y. G. and Stanley, E. R. (2003) Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol. Cell. Proteomics 2, 1143–1155.

49.	Yoshida, H., Hayashi, S., Kunisada, T., et al. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442–444.

Comments (Loading...)

Post comment/View all comments